Skip to Content

Adynxx Inc

Rating as of

Company Profile

Business Description

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

100 Pine Street, Suite 500
San Francisco, CA, 94111
T +1 415 512-7740
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2019
Fiscal Year End Dec 31, 2019
Stock Type Distressed
Employees 6